Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

VISTA Expression Associated With CD8 Confers A Favorable Immune Microenvironment And Better Overall Survival In Hepatocellular Carcinoma

M. Zhang, Huajin Pang, W. Zhao, Yu-fa Li, L. Yan, Zhong-yi Dong, X. He
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BackgroundHepatocellular carcinoma (HCC) often arises in the setting of chronic inflammation with multiple inhibitory immune signals. V-domain Ig suppressor of T cell activation (VISTA) is identified as a novel negative checkpoint regulator. This study sought to determine the expression and prognostic value of VISTA in HCC and classify tumor microenvironments (TMEs) based on VISTA and CD8+ tumor-infiltrating lymphocytes (TILs).MethodsThe expression of VISTA and CD8 proteins was assessed in 183 HCC tissue microarrays (TMAs) by immunohistochemistry (IHC). VISTA and CD8A mRNA extracted from 372 patients with HCC in The Cancer Genome Atlas (TCGA) database was included as a validation cohort. Associations between the VISTA, clinicopathological variables, and survival were analyzed.ResultsVISTA expression was detected in 29.5% HCC tissues, among which 16.4% tissues were positive for tumor cells (TCs), and 16.9% tissues were positive for immune cells (ICs). VISTA expression was significantly associated with tissues with a high pathological grading (p = 0.038), without liver cirrhosis (p = 0.011), and with a high density of CD8 + TILs (p < 0.001). Kaplan-Meier curves demonstrated that patients with VISTA-positive staining in TCs (p = 0.037), but not in ICs, (p = 0.779) showed significantly prolonged overall survival (OS) than those with VISTA-negative expression. Classification of HCC TME-based VISTA and CD8 + TILs showed 4 immune subtypes: VISTA+/CD8+ (16.9%), VISTA+/CD8- (12.6%), VISTA-/CD8+ (16.4%), and VISTA-/CD8+ (54.1%). The dual positive VISTA+/CD8+ subtype showed significantly prolonged OS than other subtypes (p = 0.023).ConclusionsVISTA protein expression in HCC showed cell specific and displayed different prognosis. VISTA expression was significantly associated with CD8 + TILs, Dual positive VISTA+/CD8+ showed favorable TME and better OS.
This paper references
Immunecheckpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J Liu (2015)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1158/1078-0432.CCR-16-2554
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-yi Dong (2016)
10.3322/canjclin.49.1.33
Global cancer statistics
D. Parkin (1999)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1158/0008-5472.CAN-13-1506
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
10.1053/j.gastro.2008.02.090
Diagnosis and treatment of hepatocellular carcinoma.
H. El-Serag (2008)
10.1038/nature21349
Elements of cancer immunity and the cancer–immune set point
D. Chen (2017)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1073/pnas.1407447111
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
L. Wang (2014)
10.1016/S0140-6736(17)31046-2
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
A. El-Khoueiry (2017)
10.1038/nrd4591
Combination cancer immunotherapy and new immunomodulatory targets
K. Mahoney (2015)
10.1038/nature14011
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
10.1053/j.gastro.2016.06.052
Regulation of Transdifferentiation and Retrodifferentiation by Inflammatory Cytokines in Hepatocellular Carcinoma.
F. Cabillic (2016)
10.1080/2162402X.2017.1293215
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Böger (2017)
10.1172/JCI75798
A VISTA on PD-1H.
Y. Liu (2014)
10.1007/s13277-016-4812-9
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
Zhong-yi Dong (2016)
10.3322/caac.20107
Global cancer statistics
A. Jemal (2011)
10.1038/nm.4308
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
10.1210/JCEM.84.8.5917
Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
N. Mitsiades (1999)
10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1073/pnas.1420370112
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
10.1158/1078-0432.CCR-15-2834
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
C.-Y. Ock (2016)
10.1158/0008-5472.CAN-15-0255
Classifying Cancers Based on T-cell Infiltration and PD-L1.
M. Teng (2015)
10.1158/1078-0432.CCR-17-2542
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
F. Villarroel‐Espíndola (2017)
10.1158/2326-6066.CIR-14-0072
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. L. Lines (2014)
10.1158/0008-5472.CAN-13-1504
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
10.1038/nature13385
Comprehensive molecular profiling of lung adenocarcinoma
E. Lander (2014)



This paper is referenced by
10.7717/peerj.10142
Mining the potential prognostic value of synaptosomal-associated protein 25 (SNAP25) in colon cancer based on stromal-immune score
Jinyan Zou (2020)
10.1007/s00432-020-03463-9
Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
Zelin Hou (2020)
10.1038/s41598-020-59608-w
Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis
X. He (2020)
10.1186/s40425-019-0749-z
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Bridget P. Keenan (2019)
10.3389/fimmu.2020.00472
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
J. M. Carballido (2020)
10.1016/j.smim.2019.101308
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A. ElTanbouly (2019)
10.1136/esmoopen-2020-000683
New emerging targets in cancer immunotherapy: the role of VISTA
M. Tagliamento (2020)
10.1002/jcb.29667
Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene‐expression–based retrospective study
Genwen Chen (2020)
10.1097/CJI.0000000000000343
High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer
Liju Zong (2020)
10.20517/2394-5079.2020.04
Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma
W. Qin (2020)
10.1097/MD.0000000000013923
Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma
Xuezhong Xu (2019)
10.1155/2020/1283632
Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix
Liju Zong (2020)
10.1007/s00109-020-01968-x
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation
M. Borggrewe (2020)
10.1111/cei.13415
VISTA: Coming of age as a multi‐lineage immune checkpoint
Mohamed A. ElTanbouly (2020)
10.3389/fonc.2020.583966
VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
Xi Cao (2020)
10.1097/MD.0000000000013301
Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma
W. Ding (2018)
10.1038/s41423-020-00572-w
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
B. Ruf (2020)
10.1186/s13046-019-1233-9
Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway
Chuanbao Cui (2019)
10.1186/s13045-020-00917-y
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang (2020)
10.1016/j.cytogfr.2020.02.002
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Geng Wang (2020)
10.1038/s41379-019-0364-z
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
S. Muller (2019)
10.1016/j.ebiom.2019.09.003
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
N. Alcala (2019)
10.1007/s00262-019-02434-5
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
Liju Zong (2019)
10.1186/s12885-020-07734-z
Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma
Junyu Huo (2021)
10.1177/1559325819884186
A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity
Weiqiang Huang (2019)
10.1007/s00262-020-02554-3
Expression of the immune checkpoint VISTA in breast cancer
Liju Zong (2020)
10.3748/wjg.v26.i2.134
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment
Fa-Peng Zhang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar